- Home
- NDMO vs MDXG Comparison
NDMO vs MDXG Comparison
Compare NDMO & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDMO | MDXG |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.2M | 625.6M |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NDMO | MDXG |
|---|---|---|
| Price | $9.16 | $4.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 210.8K | ★ 935.2K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $9.09 | $3.03 |
| 52 Week High | $10.82 | $7.97 |
Technical Indicators
Market Signals| Indicator | NDMO | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 26.78 | 64.62 |
| Support Level | N/A | $4.11 |
| Resistance Level | $10.47 | $4.76 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 11.05 | 91.11 |
Price Performance
Historical ComparisonAbout NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.